Nkarta, Inc. (NKTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Paul J. Hastings.
NKTX has IPO date of 2020-07-10, 157 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $163.26M.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
